09.03.2018 • NewsDede WillamsfraudPharma

“Pharma Bro” Ordered to Pay $7.4 Million

Pharma Bro Martin #Shkreli who gained notoriety by jacking up the price of a...
"Pharma Bro" Martin #Shkreli who gained notoriety by jacking up the price of a life-saving drug 5,000% was ordered by a federal judge to forfeit almost $7.4 million for cheating investors in his hedge fund (c) ER_09/Shutterstock

Martin Shkreli, who gained notoriety in 2015 for jacking up the price of Daraprim (pyrimethamine), a 62-year-old drug used to treat toxoplasmosis, has been ordered by a US federal judge to pay almost $7.4 million for defrauding investors in hedge funds he ran, as well as for a fraud scheme involving Retrophin, a drugmaker he founded.

The eccentric former CEO of Turing Pharmaceuticals, who called himself “Pharma Bro”, is currently serving jail time on the fraud charges. The 5000% rise in the price of the drug was legal.

Shkreli argued that he should not have to pay anything – or very little – for the crimes he is accused of because he derived no profit from them. Investors’ money went into the stock market, and the fund manager made no money from his plan to control Retrophin shares, his lawyers asserted. 

During the trial, which he called “a witch hunt of epic proportions,” and in a YouTube video, Shkreli predicted that his penalty would be “close to nil.”

While defense lawyers noted that investors ultimately got their money back, the prosecution argued that they lost more than $20 million, as they were induced to put millions of dollars into Shrkreli’s two hedge funds, which operated essentially like Ponzi schemes, while he spent their money on personal expenses.

Among assets that may be confiscated to pay the fine are said to be a Picasso original painting, $5 million in Shkreli’s personal trading account, a one-of-a-kind special edition album by the Wu-Tang Clan and his shares in Vyera Pharmaceuticals, as Turing was renamed.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.